Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$5.25 USD

5.25
223,956

+0.16 (3.14%)

Updated Aug 12, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.

    What's in Store for Catalyst (CPRX) This Earnings Season?

    by Zacks Equity Research

    Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

      What's in the Cards for Merrimack (MACK) in Q3 Earnings?

      by Zacks Equity Research

      Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

        What's in the Cards for Repros (RPRX) This Earnings Season?

        by Zacks Equity Research

        Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

          Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

          by Zacks Equity Research

          Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

            Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

            by Zacks Equity Research

            Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

              Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

              by Zacks Equity Research

              Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

                by Zacks Equity Research

                Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                  AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

                  by Zacks Equity Research

                  AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

                    Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

                    by Zacks Equity Research

                    Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.

                      Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

                      by Zacks Equity Research

                      Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.

                        Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

                        by Zacks Equity Research

                        Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

                          Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

                          by Zacks Equity Research

                          Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

                            Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

                            by Zacks Equity Research

                            Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

                              Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?

                              by Zacks Equity Research

                              Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.

                                Is a Beat in Store for Ionis (IONS) This Earnings Season?

                                by Zacks Equity Research

                                Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

                                  Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

                                  by Zacks Equity Research

                                  Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

                                    Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

                                    by Zacks Equity Research

                                    Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

                                      What to Expect from Keryx (KERX) This Earnings Season?

                                      by Zacks Equity Research

                                      Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

                                        What's in Store for Intrexon (XON) This Earnings Season?

                                        by Zacks Equity Research

                                        Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.

                                          Will Endocyte (ECYT) Disappoint This Earnings Season?

                                          by Zacks Equity Research

                                          Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

                                            Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?

                                            by Zacks Equity Research

                                            Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.

                                              Is a Beat in the Cards for Mylan (MYL) This Earnings Season?

                                              by Zacks Equity Research

                                              Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.

                                                What's in the Cards for Prothena (PRTA) in Q3 Earnings?

                                                by Zacks Equity Research

                                                Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

                                                  What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?

                                                  by Zacks Equity Research

                                                  Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.